#BREAKINGNEWS: The FDA has granted Breakthrough Therapy Designation for our #ADC for certain previously treated patients with metastatic #BreastCancer. This is the 11th designation across the Daiichi Sankyo oncology pipeline. Click the image for more information on the filing and what it may mean for patients impacted by these cancers.
Daiichi Sankyo US
Pharmaceutical Manufacturing
Basking Ridge, NJ 190,065 followers
We create life-changing solutions for patients.
About us
At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8
- Website
-
https://daiichisankyo.us/
External link for Daiichi Sankyo US
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basking Ridge, NJ
- Type
- Public Company
- Specialties
- Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo group of companies and is focused on the development of oncology therapies and specialty medicines., Oncology, and Specialty Medicine
Locations
-
Primary
211 Mt. Airy Road Basking Ridge
Basking Ridge, NJ 07920, US
Employees at Daiichi Sankyo US
-
Jak (J. C.) DeTemple
Top Talent Executive Recruiter to the Biotech/Pharma Industry Leadership Superstars! Top Talent Sourcing Guru! Talent Acquisition & Retention…
-
Hayes Williams
Global Head of Data Governance at Daiichi Sankyo, Inc.
-
Desmon Swanston
-
Joseph Prikazsky
Pharma/Biotech Financial Professional
Updates
-
Every person has the power to make their goals a reality—at home and at work. Today is a reminder that you’re not alone in that journey. Our Women's Forum Business Employee Resource Group (BERG) recently celebrated Women’s Equality Day with a powerful session on fostering an inclusive and supportive environment that champions women at all levels. 🔽 We do this through: ✨ Mentorship: Formally within Daiichi Sankyo and through partnerships with external professional organizations like Healthcare Businesswomen’s Association, Women of Color in Pharma (WOCIP) and Latinos in Bio ✨ Professional development: Providing resources and opportunities for skill enhancement, leadership training, and personal growth ✨ Allyship: Encouraging all employees in advocating for gender equality, both within our organization and in the broader community. We strive to empower every woman in our workforce and contribute to a world where equality is not just a goal but a reality. 💬 How are you making your goals a reality? #WomensEqualityDay #Empowerment #DSProud
-
-
As Daiichi Sankyo US Global Team Lead, Oncology R&D, Dalila Sellami has seen firsthand the impact a new medicine can have on a patient and their family. Motivated, committed and passionate—she’s got that true “craftsperson’s spirit.” Watch the new episode “Where Craft Meets – Medicine” only on YouTube: https://bit.ly/471VU1G #WhereCraftMeets #oncology #cancer #innovation
-
Great read on our first Chief Compliance Officer, Matt Allegrucci and how he plans to use his 20 years of DS experience to develop a global compliance program and infrastructure.
We’re pleased to introduce our new Chief Compliance Officer Matt Allegrucci. A proven leader of more than 20 years at Daiichi Sankyo, Matt has been tasked with developing the company’s first global compliance program and infrastructure. The program will focus on maintaining trust at the center of Daiichi Sankyo’s growth and transformation. “The trust of patients, physicians and everyone with a stake in our business is essential to the long-term success of the organization and our mission. The job of compliance, simply put, is to ensure we earn that trust.” Click to read how the importance of trust was instilled in Matt at a young age and became a central tenet of his career—and how he and his team help make compliance training fun. Passion for Innovation. Compassion for Patients.®
Keeping Integrity and Trust at the Center of Global Transformation - Chief Compliance Officer, Matt Allegrucci
daiichisankyo.com
-
Our mission at Daiichi Sankyo US is to contribute to the enrichment of quality of life around the world—for healthcare providers, patients and caregivers, our teams and more. A key component of that mission is understanding, encouraging and enacting empathy. "Teams that achieve empathy perform better. They understand each other so well they reach a whole new level of clarity." - David Burkus in Best Team Ever For Christina Sell, one of our Coaches of the Year, empathy is her craft and why presenting on Compassion Fatigue so important for her team's success. "From my perspective, it's critical that my team not only presents on compassion fatigue and burnout, but also believe in the message and lead by example so that we may help our fellow healthcare professionals." #DSProud #Leadership #Empathy
-
🎧 What happens if you really listen? You connect, you empathize, and sometimes, you find your true calling. As a teenager, Simon King, Chief People Officer at Daiichi Sankyo US, got to know a female patient with cancer—a relationship that changed the trajectory of his life. Simon’s experience led him to pursue a career in science and sparked in him a genuine desire to understand and help others. 🔗 Read Simon’s story, including how his unique craft contributes to Daiichi Sankyo’s collective craft of creating innovative medicines for the patients of today and tomorrow. https://bit.ly/3SMknSH #DSProud
-
-
Each year The Galien Foundation highlights the latest scientific advancements. It is inspiring to see how far the industry has come in providing treatment options for patients and humbling to know how far we still need to go. To have our HER2 directed #ADC nominated once again for the #PrixGalien Best Biotechnology Product award reflects our team’s passion for innovation and, most importantly, our unwavering focus to help change the standards of care for the patients of today and tomorrow. Thank you to all the nominees and entire oncology community for your continued commitment to patients. Click the image to read more about this prestigious award. #biotechnology #awards
The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
prnewswire.com
-
At Daiichi Sankyo US, we are committed to fostering an environment that embraces each person's unique crafts, faces challenges head on and celebrates the victories of those we serve. 🏥💪 "Team empowerment" is the leadership craft that David L. Merlob, M.S., one of our Coaches of the Year, embodies and a key element of what helps ensure our core values—innovation, integrity and accountability—are more than just words for his team. "We strive to foster a culture where challenges are embraced, and learnings are shared, with a deep understanding that our work directly impacts the patients we serve, making their victories our victories. This team embodies the spirit of collaboration, innovation, and mutual support, and I'm proud to witness their growth and success every day." #DSProud #Inspiration #Culture
-
Daiichi Sankyo US and Merck today announced an agreement to expand their existing global development and commercialization collaboration of three investigational DXd ADCs to include Merck’s investigational delta-like ligand 3 (DLL3) targeting T-cell engager. The expansion of a DLL3 T-cell engager within Daiichi Sankyo US oncology pipeline further supports the company’s ongoing R&D strategy to create new standards of care for people with cancer. Through this expanded agreement, the companies will evaluate the combination of the investigational DDL3 targeting T-cell engager with the investigational B7-H3 directed DXd ADC targeting the underlying biology of small cell lung cancer along with other forms of cancer. Read the press release for additional information on the expanded agreement and to learn more about our collective commitment to develop innovative medicines to help people impacted by cancer.
Press Releases - Daiichi Sankyo US
daiichisankyo.us
-
Biomarker testing has transformed the cancer treatment landscape, significantly improving patient outcomes by identifying ‘actionable’ targets. Just as each lung cancer patient is unique, so too should be their treatment approach. Learn more about how we are advancing biomarker awareness and driving treatment innovations: https://bit.ly/3YpMBWM #BiomarkerTesting #WorldLungCancerDay